Pharma BD Deal Intelligence
Takeda acquired Nimbus Lakshmi for $6B for TYK2 inhibitor for autoimmune diseases.
Takeda will acquire all shares of Nimbus Lakshmi for $4 billion upfront plus up to $2 billion in sales-based milestones, gaining NDI-034858 (TAK-279), an oral…
Phase 3 Latitude PsO 3001/3002: sPGA 0/1 71.4%/69.2% vs apremilast 32.1%/29.7% and placebo 10.7%/12.6% at wk16; PASI 90 61.3%/51.9%. On track to submit NDA to…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Takeda acquired Nimbus Lakshmi for $6B for TYK2 inhibitor for autoimmune diseases.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi (this deal) | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
| Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. | 2026 | $600M | 54 |
← Browse all deals · How we score deals
More: 2022 deals · Takeda Pharmaceutical Company Ltd. deals · Dermatology deals